Free Trial

Haleon (HLN) Stock Forecast & Price Target

Haleon logo
$8.85 +0.06 (+0.63%)
As of 12:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
6
Buy
4

Based on 10 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 6 have given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for HLN.

Consensus Price Target

$12.33
39.34% Upside
According to the 10 analysts' twelve-month price targets for Haleon, the average price target is $12.33. The highest price target for HLN is $13.40, while the lowest price target for HLN is $11.25. The average price target represents a forecasted upside of 39.34% from the current price of $8.85.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HLN Analyst Ratings Over Time

TypeCurrent Forecast
10/7/24 to 10/7/25
1 Month Ago
9/7/24 to 9/7/25
3 Months Ago
7/9/24 to 7/9/25
1 Year Ago
10/8/23 to 10/7/24
Strong Buy
1 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
6 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.33$12.33$12.33$10.95
Forecasted Upside39.34% Upside26.05% Upside22.51% Upside9.06% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyBuy

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haleon Stock vs. The Competition

TypeHaleonMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside38.72% Upside1,307.85% Upside169.94% Upside
News Sentiment Rating
Very Positive News

See Recent HLN News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C)
9/16/2025Barclays
3 of 5 stars
Warren Ackerman
Not Rated
DowngradeOverweightEqual Weight
9/10/2025The Goldman Sachs Group
3 of 5 stars
 UpgradeNeutralBuy
5/27/2025BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
5/27/2025BNP Paribas Exane
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralOutperform$13.40+20.07%
5/9/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeEqual WeightOverweight$11.25+6.38%
3/5/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
3/5/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuyHold
3/3/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHold
1/8/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
10/1/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/6/2024Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
3/26/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:57 PM ET.


Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 4, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Haleon plc:

  • The company has recently increased its semi-annual dividend to $0.0555, reflecting a strong commitment to returning value to shareholders. This increase from the previous dividend indicates positive financial health and growth potential.
  • Haleon plc has a market capitalization of approximately $43.35 billion, suggesting a stable and significant presence in the consumer healthcare market, which can be attractive for long-term investors.
  • With a current price-to-earnings (P/E) ratio of around 24.83, the stock may be considered reasonably valued compared to its earnings, which can indicate potential for future growth.
  • Recent upgrades from analysts, including a "strong-buy" rating from BNP Paribas and a "buy" rating from Goldman Sachs, suggest positive sentiment and confidence in the company's future performance.
  • The current stock price is around $12.33, which is close to the average price target set by analysts, indicating that the stock may have room for appreciation based on market expectations.

Haleon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Haleon plc for these reasons:

  • The PEG ratio of 2.90 suggests that the stock may be overvalued relative to its earnings growth, which could deter value-focused investors.
  • Analysts have mixed ratings, with some recent downgrades, including a reduction from "overweight" to "equal weight" by Barclays, indicating potential concerns about the stock's performance.
  • The beta of 0.23 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • The dividend payout ratio of 28.21% suggests that a significant portion of earnings is being returned to shareholders, which could limit the funds available for reinvestment in growth initiatives.
  • Market sentiment can be influenced by broader economic conditions, and any downturn in the consumer healthcare sector could negatively impact Haleon plc's stock performance.

HLN Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $12.33, with a high forecast of $13.40 and a low forecast of $11.25.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last twelve months. There are currently 6 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HLN shares.

According to analysts, Haleon's stock has a predicted upside of 39.34% based on their 12-month stock forecasts.

Over the previous 90 days, Haleon's stock had 1 upgrade and 1 downgrade by analysts.

Haleon has been rated by research analysts at Barclays, The Goldman Sachs Group, and Weiss Ratings in the past 90 days.

Analysts like Haleon more than other "medical" companies. The consensus rating for Haleon is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how HLN compares to other companies.


This page (NYSE:HLN) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners